SL
ALNY icon

Savior LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Savior LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52
Closed -$9K – 210
2021
Q2 		$9K Hold
52
– – 0.01% 427
2021
Q1 		$7K Hold
52
– – 0.01% 478
2020
Q4 		$7K Hold
52
– – 0.01% 476
2020
Q3 		$8K Hold
52
– – 0.01% 404
2020
Q2 		$8K Hold
52
– – 0.01% 363
2020
Q1 		$6K Hold
52
– – 0.01% 400
2019
Q4 		$6K Buy
+52
New +$5.18K 0.01% 529

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Savior LLC's ALNY Position: Q3 2021 in Review

Savior LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 52 shares — an estimated $9K sold.

Savior LLC first reported a position in ALNY in Q4 2019 and held it in 7 quarters. The position peaked at $9K in Q2 2021. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • Savior LLC reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Savior LLC sold 52 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $9K.
  • Savior LLC first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Savior LLC's Alnylam Pharmaceuticals position peaked at $9K in Q2 2021.
  • 405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Savior LLC's 13F filing for Q3 2021, filed 5 Oct 2021.